- UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio s existing early stage monoclonal antibodies.
LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2 - read this article along with other careers information, tips and advice on BioSpace
- UK-based RQ Biotechnology Ltd (RQ Bio) launches with funding from licensing deal with AstraZeneca for RQ Bio's existing early stage monoclonal antibodies (mAbs) against SARS-CoV-2 with payments
AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio's existing early-stage monoclonal antibodies (mAbs) against SARS-CoV-2 and right to exclusively
Two doses of Covid vaccines induce lower antibody levels against Omicron: Oxford study - Jammu Kashmir Latest News | Tourism dailyexcelsior.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailyexcelsior.com Daily Mail and Mail on Sunday newspapers.